The current randomized controlled superiority trial compared exercise therapy to arthroscopic partial meniscectomy
in patients ages 35 to 60 years presenting to the orthopedic departments of 2 hospitals in Norway with unilateral knee pain for more than 2 months and an MRI-delineated medial meniscal tear.
T]he results of this randomized, sham-controlled trial show that arthroscopic partial medial meniscectomy
provides no significant benefit over sham surgery in patients with a degenerative meniscal tear and no knee osteoarthritis.
They were randomized evenly to a standardized PT regimen emphasizing strength and range of motion, or to arthroscopic partial meniscectomy
accompanied by standardized PT.
Arthroscopic joint examination was conducted and all results were found parallel with the pre-surgery diagnosis; after preliminary assessment regarding the torn meniscus part, either total or partial meniscectomy
The research included 146 patients, aged 35 to 65, and the results showed that the improvement in knee pain in patients who had meniscectomy
was similar to the improvement experienced by patients who'd had sham surgery.
Teppo Jarvinen, a surgeon at the University of Helsinki in Finland, enrolled 146 patients between the ages of 35 and 65 who had knee pain for at least three months in a trial in which they were randomized to either undergo an arthroscopic partial meniscectomy
or a "sham" procedure that mimics an arthroscopy.
The effectiveness of 5 mg intraarticular morphine injection following Anterior cruciate ligament reconstruction and in meniscectomy
had been shown before as well as in this study.
Joint instability was induced in surgical models by partial meniscectomy
combined with transaction of collateral and cruciate ligaments (Bendele 2001; Pmonis et al.
At the moment surgeons often perform a meniscectomy
to trim or remove the torn cartilage, which reduces pain, but increases the long term risk of osteoarthritis.
The prevalence of gonarthrosis and its relation to meniscectomy
in former soccer players.
Biopharmaceutical company Omeros Corporation (NasdaqGM:OMER) on Wednesday announced that it has initiated enrolment in the first of two planned Phase 3 clinical trials evaluating OMS103HP in patients undergoing arthroscopic partial meniscectomy
These include covering the costs associated with its two Phase III clinical development programmes involving its main product candidates: OMS103HP for use during arthroscopic partial meniscectomy
surgery and OMS302 for application during intraocular lens replacement procedures.